Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026
Strengthened board and executive leadership with deep immunology, commercial and financial expertise
Robust balance sheet with cash, cash equivalents and investments of
“2025 was a year of strong execution as we advanced our AlloNK program, successfully enrolling patients in community settings across autoimmune indications and prioritizing refractory RA as our lead indication,” said
Recent Business Highlights
- Prioritized refractory RA as lead indication: Received FDA Fast Track designation for AlloNK in refractory RA and prioritized RA as the program’s lead autoimmune indication.
- Despite multiple approved biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs), there are more than 150,000 RA patients in the
U.S. who have failed at least two prior therapies. Real-world data suggest ACR50 response rates at six months are typically in the 10 – 20% range, underscoring the significant unmet need and opportunity for AlloNK plus rituximab to drive deeper and more durable responses with a single treatment cycle. - Artiva has successfully enrolled refractory RA patients across dose levels and will provide initial clinical response data from at least 15 patients, most of whom are expected to have six or more months of follow-up, in the first half of 2026.
- Despite multiple approved biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs), there are more than 150,000 RA patients in the
- Demonstrated deep and consistent B-cell depletion supporting intended mechanism of action: Across patients analyzed, AlloNK plus rituximab resulted in non-quantifiable peripheral CD19+ B-cell levels by Day 13. These findings were confirmed using a high-sensitivity assay with 10- to 50-fold greater sensitivity than standard assays. Early reconstitution data demonstrated predominantly naïve and transitional B cells, consistent with immune reconstitution patterns observed with CD19-directed autologous CAR-T therapies.
- Established favorable safety and outpatient feasibility profile in autoimmune disease, leading to strong enrollment: As of the
Oct. 1, 2025 data cutoff, 32 patients were treated with AlloNK plus rituximab across refractory RA, Sjögren’s disease, systemic lupus erythematosus (SLE), lupus nephritis and systemic sclerosis, entirely in the outpatient setting, with the majority treated in community rheumatology clinics. The regimen was well tolerated, with no reported cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), graft-versus-host disease or hypogammaglobulinemia. - Reported continued durability in Phase 1/2 oncology trial: Presented longer-term data from the completed Phase 1/2 trial of AlloNK plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma demonstrating a 64% complete response rate and a median duration of response not yet reached, exceeding 19.4 months at data cutoff, in line with commercially approved auto-CAR-T results in a comparable patient population.
- Enhanced executive leadership to support late-stage development and capital strategy: Appointed
Subhashis Banerjee , M.D. as chief medical officer andThad Huston as chief financial officer, adding deep rheumatology development expertise, regulatory experience and global financial leadership as AlloNK advances toward potential registrational development. - Strengthened board leadership with deep immunology and commercial expertise: Appointed
Dan Baker , M.D. andElaine Sorg to the board of directors, adding extensive experience in autoimmune drug development, regulatory strategy and large-scale immunology commercialization, including leadership roles supporting major therapies for rheumatoid arthritis and other immune-mediated diseases in multibillion dollar franchises.
Upcoming Milestones
- Initial clinical response data in refractory RA expected in the first half of 2026: Artiva expects to report initial clinical response data in at least 15 patients, most of whom are expected to have six or more months of follow-up.
- Planned FDA interaction in the first half of 2026 to discuss potential pivotal trial design in refractory RA: Subject to feedback and alignment with the FDA, AlloNK has the potential to become the first deep B-cell depleting therapy to initiate a pivotal trial in patients with refractory RA.
Full Year 2025 Financial Results
- Cash, Cash Equivalents and Investments. As of
December 31, 2025 , Artiva had cash, cash equivalents, and investments of$108.0 million , which is expected to fund operations into Q2 2027. - License and Development Support Revenue. License and development support revenue was zero for the year ended
December 31, 2025 , compared to$0.3 million for the year endedDecember 31, 2024 . - Research and Development Expenses. Research and development expenses were
$69.5 million for the year endedDecember 31, 2025 , compared to$50.3 million for the year endedDecember 31, 2024 . - General and Administrative Expenses. General and administrative expenses were
$20.3 million for the year endedDecember 31, 2025 , compared to$17.2 million for the year endedDecember 31, 2024 . - Other Income, net. Other income, net, was
$5.9 million for the year endedDecember 31, 2025 , compared to other income, net, of$1.9 million for the year endedDecember 31, 2024 . - Net Loss. Net loss totaled $83.9 million for the year ended
December 31, 2025 , as compared to net loss of$65.4 million for the year endedDecember 31, 2024 , with non-cash stock-based compensation expense of$6.8 million and$7.0 million for the years endedDecember 31, 2025 and 2024, respectively.
About
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly
Artiva is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of
Condensed Balance Sheets(unaudited) (in thousands) | ||||||||
| Assets | ||||||||
| Cash, cash equivalents and investments | $ | 108,008 | $ | 185,428 | ||||
| Property and equipment, net | 6,618 | 6,370 | ||||||
| Operating and financing lease right-of-use assets | 10,737 | 14,055 | ||||||
| Other assets | 5,577 | 3,728 | ||||||
| Total assets | $ | 130,940 | $ | 209,581 | ||||
| Liabilities and stockholders' equity | ||||||||
| Accounts payable and accrued expenses | $ | 9,955 | $ | 8,513 | ||||
| Operating and financing lease liabilities | 10,942 | 14,354 | ||||||
| Other liabilities | 73 | 73 | ||||||
| Total liabilities | 20,970 | 22,940 | ||||||
| Stockholders' equity | 109,970 | 186,641 | ||||||
| Total liabilities and stockholders' equity | $ | 130,940 | $ | 209,581 | ||||
Condensed Statements of Operations and Comprehensive Loss (unaudited) (in thousands, except share and per share data) | ||||||||
| Year Ended | ||||||||
| 2025 | 2024 | |||||||
| License and development support revenue | $ | – | $ | 251 | ||||
| Operating expenses: | ||||||||
| Research and development | 69,540 | 50,328 | ||||||
| General and administrative | 20,270 | 17,205 | ||||||
| Total operating expenses | 89,810 | 67,533 | ||||||
| Loss from operations | (89,810 | ) | (67,282 | ) | ||||
| Other income, net: | ||||||||
| Interest income | 5,959 | 5,349 | ||||||
| Change in fair value of SAFEs | – | (3,597 | ) | |||||
| Other (expense) income, net | (14 | ) | 157 | |||||
| Total other income, net | 5,945 | 1,909 | ||||||
| Net loss | $ | (83,865 | ) | $ | (65,373 | ) | ||
| Net loss per share, basic and diluted | $ | (3.43 | ) | $ | (5.81 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 24,444,057 | 11,258,851 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (83,865 | ) | $ | (65,373 | ) | ||
| Other comprehensive income (loss), net | 232 | (437 | ) | |||||
| Comprehensive loss | $ | (83,633 | ) | $ | (65,810 | ) | ||
Contacts
Investors
Noopur Batsha Liffick, MPH
ir@artivabio.com
Media
jessica@litldog.com
Source:
